Results 1 to 10 of about 2,650 (185)

Brolucizumab in Pretreated Neovascular Age-Related Macular Degeneration: Case Series, Systematic Review, and Meta-Analysis [PDF]

Life, 2023
Background: Recalcitrant neovascular age-related macular degeneration (rnAMD) despite intensive intravitreal anti-neovascular endothelial growth factor (VEGF) treatment, can be handled by switching to another anti-VEGF agent. This first systematic review
Christof Hänsli, Christin Schild, Isabel Pfister, Justus G. Garweg   +3 more
doaj   +3 more sources

Off-label intravitreal brolucizumab and bevacizumab for chronic central serous chorioretinopathy [PDF]

International Journal of Ophthalmology
AIM: To compare the intravitreal brolucizumab and bevacizumab injections for chronic central serous chorioretinopathy (cCSC). METHODS: Patients with cCSC were classified into bevacizumab and brolucizumab group.
Jung Yeon Joo, Yong Hyun Jun, Seong Taeck Kim   +2 more
doaj   +2 more sources

Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy

Biomedicines, 2021
We compared the short-term outcomes between 3-monthly aflibercept and brolucizumab injections for treatment-naïve polypoidal choroidal vasculopathy (PCV). A total of 52 eyes were included.
Yoichi Sakurada, Kenji Kashiwagi
exaly   +3 more sources

Comparison of Three Consecutive Monthly Administrations Between Aflibercept 8 mg and Brolucizumab 6 mg in Polypoidal Choroidal Vasculopathy [PDF]

Pharmaceuticals
Purpose: The aim was to compare the short-term outcomes of aflibercept 8 mg and brolucizumab for the treatment of polypoidal choroidal vasculopathy (PCV). Methods: This study included 48 eyes of 48 patients with PCV.
Yoshiko Fukuda, Yoichi Sakurada, Yumi Kotoda, Misa Kimura, Kenji Kashiwagi   +4 more
doaj   +2 more sources

Side Effects of Brolucizumab [PDF]

Journal of Ophthalmic & Vision Research, 2021
Age-related macular degeneration and its complication, subretinal neovascularization, are common causes of progressive, irreversible impairment of central vision. Anti-vascular endothelial growth factor (anti-VEGF) therapy has improved the visual outcome
Tahmineh Motevasseli, Saeed Mohammadi, Fatemeh Abdi, William R. Freeman   +3 more
doaj   +5 more sources

Effectiveness, Safety, and Real-World Experience of Brolucizumab: A Systematic Review [PDF]

Pharmaceuticals
Background/Objectives: Brolucizumab is a humanized single-chain antibody fragment with a molecular weight of approximately 26 kilodaltons (scFv, ~26 kDa) targeting all VEGF-A isoforms.
Naif M. Alali, Abeer Aljahdali, Hani B. AlBalawi, Othman Jarallah Al Jarallah, Salem Mohammed AL Zaid, Ismail Abuallut, Faisal ALMarek, Ibrahim Shajry, Yousef A. Alotaibi, Mohammad A. Hazzazi, Moustafa S. Magliyah   +10 more
doaj   +2 more sources

Aflibercept and Brolucizumab in Diabetic Macular Edema: A Focused Review of Efficacy, Safety, and Clinical Considerations [PDF]

Biomedicines
Background/Objectives: Diabetic macular edema (DME) are major causes of visual impairment worldwide, with vascular endothelial growth factor (VEGF) playing a central role in disease pathogenesis.
Ana Maria Dascalu, Catalin Cicerone Grigorescu, Ece Ergin, Cristina Alexandrescu, Dan Dumitrescu, Marina Ionela Nedea, Bogdan Mihai Cristea, Dragos Serban, Laura Carina Tribus, Tudor Mihai Badescu   +9 more
doaj   +2 more sources

First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration

Frontiers in Pharmacology, 2022
Purpose: To assess the morphological and functional outcomes within the first year of treatment with intravitreal brolucizumab for refractory neovascular age-related macular degeneration (nAMD).Methods: This retrospective study included 21 eyes from 19 ...
Alaa Din Abdin, Isabel Weinstein, Berthold Seitz   +2 more
exaly   +3 more sources

Efficacy of Intravitreal Brolucizumab Switch in Pachychoroid Neovasculopathy [PDF]

Ophthalmology and Therapy
Introduction This study aimed to evaluate the anatomical and functional outcomes of switching to intravitreally administered brolucizumab (Beovu®, Novartis) in patients affected by pachychoroid neovasculopathy (PNV) who were considered as non-responders ...
Nicolò Ribarich, Marco Battista, Lisa Checchin, Riccardo Sacconi, Francesco Bandello, Giuseppe Querques   +5 more
doaj   +2 more sources

Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations

American Journal of Ophthalmology Case Reports, 2020
Purpose: To describe a case of unilateral retinal arteriolar occlusion following multiple intravitreal brolucizumab injections for neovascular age-related macular degeneration (nAMD).
Wataru Matsumiya
exaly   +3 more sources